Overview
Rifaximin is an antibiotic used to treat bacterial infections in the intestines

Coverage Guidelines
Xifaxan may be approved when all the following diagnosis-specific criteria has been met and documentation has been provided:

1. Member has a diagnosis of hepatic encephalopathy (550mg) AND is currently receiving treatment with Xifaxan excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.
   OR
   a. Member has had an inadequate response or has a contraindication to a lactulose product
   b. Member is at least 18 years of age

2. Member has a diagnosis of Irritable Bowel Syndrome with Diarrhea AND
   a. Member has had an inadequate response or has a contraindication to loperamide or diphenoxylate/atropine AND a bile sequestrant (e.g., cholestyramine, colestipol, colesevelam)
   b. Member is at least 18 years of age

Limitations
1. The following quantity limits apply:
   - Hepatic Encephalopathy: 550mg twice a day; 60 tablets per 30 days
   - IBS w/Diarrhea: 550mg three times a day x 14 days; 42 tablets per 14 days – May be treated up to 2 times with this regimen
References
2. Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; January 2018
3. Prevalite (cholestyramine) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories Inc; August 2017
5. Lactulose Solution [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co Inc; March 2013

Review History
06/19/2019 – Reviewed
05/20/2020 – Reviewed May P&T Mtg; No clinical updates

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.